Andy Knight

Oncology Fellow | Massachusetts General Hospital/DFCI | @MassGenBrigham | #Melanoma | #Immunotherapy

[Andy Knight @AndyKnightMD]

I matched at @DanaFarber for Heme/Onc fellowship!!! I cannot express how excited I am! Thank you to my incredible mentors and everyone who supported me through this process. I can't wait for this next chapter. @KarapetLilit @jmkirkwood @YanaNajjarMD @LenAppleman @jasonlukemd

[Andy Knight @AndyKnightMD]

Great work Sabrina — well deserved opportunity! 🎉

[Sabrina Bruno @SabrinaBruno_]

Grateful for the opportunity to present at the Living With Melanoma Symposium. Thank you to my mentors @jmkirkwood @AndyKnightMD, and to @AIMatMelanoma @UPMCHillmanCC for hosting. Most importantly, thank you to the patients whose sample donations made this work possible.

[Diwakar Davar, M.D. @diwakardavar]

3 new #NatureMedicine trials show FMT can boost ICI activity across tumors:
• TACITO – mRCC PFS benefit
• PERFORM – encapsulated FMT + ICI feasibility
• FMT-LUMINate – ORR 80% NSCLC, 75% melanoma
Microbiome engineering is entering oncology (https://t.co/c7KkLQjAcq).

[Diwakar Davar, M.D. @diwakardavar]

Excellent presentation by @MeghanMooradian from
@DFCI presenting @UPMCHillmanCC led Neo-Mel-T trial evaluating neoadjuvant anti-TIM-3+anti-PD-1 vs. neoadjuvant anti-PD-1 in high-risk resectable #melanoma. MPR 56%, 1-year RFS 87% with no surgical delays, 15%TRAE with dostar/cobo

[Andy Knight @AndyKnightMD]

Join us tomorrow for virtual morning report!

[The Clinical Problem Solvers @CPSolvers]

#MedTwitter - Grab your morning coffee and plan your week with us!☕️

We can't wait to see you at this week's sessions!🙂

Join our live sessions for free using the link➡️https://t.co/7jq32u0wk4

[Jason Luke, MD, FACP, FASCO @jasonlukemd]

Extremely excited re: IMA203 - PRAME TCR T cells Ph 1 study published in @NatureMedicine! This is a transformative Rx in #melanoma for HLA-A201+ & PD1 refractory pts. Compared to TIL, easier to make, less toxic & so far ~2x response rate in heavily pre-Rx.
https://t.co/HVgl1QRQfQ

[Andy Knight @AndyKnightMD]

Come join Dr. Vidula from @MGHBreastOnc and me for @CPSolvers morning report!

[The Clinical Problem Solvers @CPSolvers]

#MedTwitter - Plan your week with us!

We have an exciting week ahead here at Clinical Problem Solvers.

Join our live sessions for free using the link➡️https://t.co/7jq32u149C

[Hassan Abushukair @HMAbushukair]

Check out our recent work on TLS and their overshadowed precursors, lymphoid aggregate, in melanoma out now in @jitcancer
I am honored to have had the chance to study and contribute to this field under Dr. @KarapetLilit who has been a tremendous supporter of me all the way 🎉

[Omid Hamid MD @OmidHamidMD]

Jeffrey S Weber's life is a testament to mentorship, patient care, sacrifice, leadership. Thank you @jitcancer for allowing us to share a glimpse of this giant.
https://t.co/IPMcAbPYj2
@jasonlukemd @BernardAFox @MoffittNews @uscnorris @nyulangone @theNCI @ASCO @CureMelanoma @MelanomaReAlli

[Allison Betof, MD, PhD, FASCO @DrBetofMDPhD]

We lost a legend today. Jeff meant so much to the fields of melanoma and immuno-oncology. We were fortunate to learn from him and share the fruits of his labor with our patients. May his memory be a blessing.

[Tony Cillo, PhD @tonyrcillo]

Excited to share our paper out today in @CellCellPress with @BcellBruno @Vignali_Lab! Part of a trio of papers, we show in #Melanoma, anti-PD1+anti-LAG3 therapy modifies CD8 differentiation to promote enhanced effector function https://t.co/FwuxRuOPJI

[Andy Knight @AndyKnightMD]

@SabrinaBruno_ @jmkirkwood Great work Sabrina!

[Sabrina Bruno @SabrinaBruno_]

Had a great time at #ASCO24 this year! Thank you to my wonderful mentors @AndyKnightMD and @jmkirkwood for the support and guidance with my project. And thank you to everyone who stopped by my poster. #Melanoma #Immunotherapy

[Jason Luke, MD, FACP, FASCO @jasonlukemd]

Nice review here on recent advancements for #melanoma developmental #immunotherapy. Great work @AndyKnightMD! Useful read as prep during your travels to #ASCO24. Bispecifics, vaccines, oncolytic virus, adoptive cell transfer, cytokines & more!
https://t.co/GBP4gDFZwN

[Pitt Medicine Chiefs @PittIMChiefs]

This is the face of very proud @PittIMChiefs @AndyKnightMD, @CaseySkittle, @valenjaramillo7 and PD @ACarterMD after witnessing the hard work and dedication of each one of our residents!
We couldn’t be more honored to be here and watch all of you grow 💜 @PittGIM @PittDeptofMed

[Andrea Carter @ACarterMD]

Outgoing and incoming @PittIMChiefs chief residents at #AIMW24!! So proud of these amazing humans. @PittGIM @PittDeptofMed

[Melanoma Research Foundation @CureMelanoma]

"My research aims to uncover any differences in treatment outcomes among patients with pre-existing type II diabetes at the time of their metastatic melanoma diagnosis. Discovering such differences could prompt further investigation, potentially influencing recommendations regarding dosage and follow-up intervals tailored specifically for this patient population."

This #MRFResearchWednesday, Read about 2024 Medical student grant recipient @SabrinaBruno_ from @PittHealthSci and her research on Outcomes and immune profile of type II diabetic patients on nivolumab. to learn more about Sabrina's research - https://t.co/hIITdc7pkH

[UPMC Hillman Cancer Center @UPMCHillmanCC]

Published in @JCO_ASCO, Dr. Jason Luke (@jasonlukemd) shares a three year update for the KEYNOTE-716 study. These results continue to support the use of pembrolizumab adjuvant therapy in patients with resected stage IIB or IIC melanoma. https://t.co/XmqjBUWvoA

[Leonard Appleman @LenAppleman]

Thanks, @DrChoueiri; and to the patients & study team, @eaonc @SWOG @ALLIANCE_org @montypal @neerajaiims @BrianCostelloMD Amie Kim, Naomi Haas, Mike Carducci, Wayne Harris @LynneWagnerPhD David Cella, Chris Ryan @JCO_ASCO @UPMCHillmanCC

[Allison Betof, MD, PhD, FASCO @DrBetofMDPhD]

Lifileucel (TIL cell therapy from @IovanceBio) is now FDA approved for advanced PD-1 refractory melanoma!!! The melanoma community is so grateful to the patients, caregivers, and clinicians who have made the clinical trials of this therapy possible and got lifileucel to approval. We are very excited to bring this life-saving therapy to patients ASAP! Available immediately at @StanfordCancer!!!

https://t.co/DELWIIdwnY

[Brittany Bromfield @brittybb]

Excited to have our abstract accepted for presentation at the upcoming #DDW2024. Thanks to my mentor @eaks790 for the support and encouragement. @BrighamGI @DDWMeeting 🥳